Skip to main content
User menu
Subscribe
Donate
The HIV Treatment Journal of
Webinars
Current Issue
Drug Guides
Trending
COVID-19 and HIV
HIV Decriminalization
Hepatitis C
U=U
HIV & Aging
HIV Basics
HIV Cure Research
HIV Prevention
HIV Treatment
Stigma & Discrimination
POZ Advocate
Archive
About
Who We Are
Advertise
Contact
Subscribe
Reader/Customer Service
News
Donate
Donate
Bulk Subscriber Donation
Search
HIV Treatment
Back to top
HIV meds just four days a week?
And other conference highlights including new long-acting drug GS-6207; PrEP on demand; HIV treatment = prevention.
By
Sep 19, 2019
Building blocks for a healthy life
Building blocks for a healthy life, with insights from a nurse educator
By
John J. Parisot, PhD, MSN, RN
Sep 10, 2019
Briefly
Sep 3, 2019
Editor's Note
Note to my younger self
By
Aug 26, 2019
Truvada Safety
Talking about PrEP and HIV treatment in a time of class action lawsuits
By
Cori Blum, MD, AAHIVS
Aug 7, 2019
Briefly
By
Jul 22, 2019
Healthiness in HIV
A look in the poster hall
By
May 20, 2019
Drugs in development
Monthly injections plus inhibitors of viral capsid and maturation
By
May 20, 2019
Briefly: May+June 2019
May 6, 2019
FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)
It's the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Apr 8, 2019
Pagination
Previous page
‹‹
Page 6
Next page
››
Subscribe to HIV Treatment